Treatment strategy for metastatic luminal HER2-negative breast cancer with germline BRCA1/2 mutations: clinical experience with olaparib

Among breast cancer cases, approximately 10% are associated with mutations in the BRCA1/2 genes, and about 50% of these cases present with a luminal HER2-negative phenotype. The standard first-line therapy for this subtype is sequential lines of hormone therapy, including combinations with various targeted drugs (CZK4/6 inhibitors, PI3K inhibitors, mTOR). PARP inhibitors are also a possible option for the treatment of metastatic BRCA-associated HER2-negative breast cancer. We present a clinical case of successful use of olaparib as a third-line therapy for metastatic luminal HER2-negative breast cancer. Through this case, we discuss the role of various treatment strategies in managing metastatic BRCA-associated luminal HER2-negative breast cancer.